Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05185739
Title Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC) (PRIMER-1)
Acronym PRIMER-1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University College, London
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
Queen Elizabeth Hospital NOT_YET_RECRUITING Birmingham United Kingdom Details
Cambridge University Hospitals NHS Foundation Trust NOT_YET_RECRUITING Cambridge United Kingdom Details
Beatson West of Scotland Cancer Centre NOT_YET_RECRUITING Glasgow United Kingdom Details
St James's Hospital, Leeds Teaching Hospital NHS Trust NOT_YET_RECRUITING Leeds United Kingdom Details
Clatterbridge Cancer Centre NOT_YET_RECRUITING Liverpool United Kingdom Details
King's College Hospital NOT_YET_RECRUITING London United Kingdom Details
Royal Free Hospital RECRUITING London United Kingdom Details
The Christie NHS Foundation Trust NOT_YET_RECRUITING Manchester United Kingdom Details
Northern Institute of Cancer Research NOT_YET_RECRUITING Newcastle Upon Tyne United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field